J&J will now explore Rybrevant's efficacy and safety in a Phase III trial in first-line, EGFR-driven HNSCC and colorectal ...

The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare ...

Paul Hastings and TriLegal have emerged as the leading mergers and acquisitions (M&A) legal advisers in the Asia-Pacific ...

A&O Shearman and CMS have emerged as the top legal advisers in terms of deal value and deal volume, respectively.

Goldman Sachs and UBS have secured their positions as the leading mergers and acquisitions (M&A) financial advisers in the ...

Wachtell, Lipton, Rosen & Katz and Kirkland & Ellis have emerged as the top M&A legal advisers in North America in terms of ...

Goldman Sachs and Houlihan Lokey have emerged as the leading mergers and acquisitions (M&A) financial advisers in North ...

Bank of America and Rothschild & Co have secured the leading positions as financial advisers in Europe's M&A sector.

Sanofi’s teplizumab, which is already FDA-approved to delay the onset of stage 3 type 1 diabetes, has been included on the ...

The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.